The majority of collagen peptides sold in the export market (Korea, USA, SA) are oriented towards B2B transactions, thereby limiting their pricing power. Gelixer (Sold in India), on the other hand, is a B2C product, but its production volume accounts for only around 1% of the total collagen peptide production.
Recording of AGM 21-22 Discussed at around 37th minute.
This video also explains the rise in the recent margins.
| Subscribe To Our Free Newsletter |
